| Title |
AXL receptor tyrosine kinase as a therapeutic target in NSCLC
|
|---|---|
| Published in |
Lung Cancer: Targets and Therapy, April 2015
|
| DOI | 10.2147/lctt.s60438 |
| Pubmed ID | |
| Authors |
Ross A Okimoto, Trever G Bivona |
| Abstract |
The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and epithelial-mesenchymal transition-associated drug resistance. Gas6 and AXL expression have been correlated with poor prognosis and advanced clinical stage in patients with lung cancer, and targeting the Gas6/AXL pathway demonstrates antitumor activity, decreases cellular invasion, and restores sensitivity in de novo and acquired drug resistance models. These findings implicate AXL as a promising therapeutic target in lung cancer. In this review, we explore the role of AXL in lung cancer progression, from tumor development to disseminated disease, and highlight the current clinical landscape of anti-AXL therapeutics. |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 2% |
| Unknown | 61 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 21% |
| Student > Bachelor | 10 | 16% |
| Student > Master | 10 | 16% |
| Other | 7 | 11% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 6 | 10% |
| Unknown | 11 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 23 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 15% |
| Agricultural and Biological Sciences | 6 | 10% |
| Medicine and Dentistry | 5 | 8% |
| Immunology and Microbiology | 1 | 2% |
| Other | 3 | 5% |
| Unknown | 15 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2023.
All research outputs
#8,713,411
of 25,806,080 outputs
Outputs from Lung Cancer: Targets and Therapy
#42
of 129 outputs
Outputs of similar age
#98,054
of 280,077 outputs
Outputs of similar age from Lung Cancer: Targets and Therapy
#1
of 2 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 129 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,077 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them